^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    pegylated liposomal doxorubicin (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Int J Gynecol Cancer
    Title:

    Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

    Published date:
    01/11/2023
    Excerpt:
    Patients with high-grade serous ovarian cancers at first platinum-sensitive relapse who received one of these doublets were included....Median progression-free survival was longer in BRCA mutated patients than in BRCA wild type patients when receiving carboplatin/pegylated liposomal doxorubicin without maintenance treatment (15.8 vs 11.8 months; p<0.001).
    DOI:
    10.1136/ijgc-2022-003993